Trials / Withdrawn
WithdrawnNCT04854486
Impact of GSE and Xylitol (Xlear) on COVID-19 Symptoms and Time to PCR Negativisation in COVID-19 Patients
Impact of GSE and Xylitol (Xlear) in Symptoms and Time to PCR Negativisation of Patients With Acute COVID-19 Infection
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Larkin Community Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Accepted
Summary
This clinical trial aims to ascertain the impact of GSE and Xylitol (XLEAR) in decreasing the time of negativisation in PCR testing in patients with COVID-19.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | GSE and Xylitol | Participants are given the experimental treatment to be used for 7 days. |
| DRUG | Control Placebo | Saline |
Timeline
- Start date
- 2021-12-16
- Primary completion
- 2022-03-30
- Completion
- 2022-11-16
- First posted
- 2021-04-22
- Last updated
- 2023-10-16
Locations
2 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04854486. Inclusion in this directory is not an endorsement.